| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft vs Host Disease | 26 | 2026 | 688 | 6.230 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 23 | 2026 | 1273 | 3.210 |
Why?
|
| Gastrointestinal Microbiome | 13 | 2026 | 828 | 3.100 |
Why?
|
| Gastrointestinal Diseases | 2 | 2026 | 336 | 1.330 |
Why?
|
| Dysbiosis | 5 | 2025 | 144 | 1.080 |
Why?
|
| Bacteria | 4 | 2026 | 521 | 1.030 |
Why?
|
| Bacteroides | 2 | 2024 | 36 | 1.020 |
Why?
|
| Feces | 4 | 2026 | 718 | 0.980 |
Why?
|
| Carbohydrate Metabolism | 1 | 2026 | 50 | 0.940 |
Why?
|
| Thrombospondins | 2 | 2018 | 14 | 0.680 |
Why?
|
| Metabolome | 2 | 2025 | 325 | 0.610 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2025 | 151 | 0.590 |
Why?
|
| Stem Cells | 4 | 2024 | 703 | 0.580 |
Why?
|
| Neutropenia | 3 | 2026 | 209 | 0.540 |
Why?
|
| Paneth Cells | 1 | 2017 | 22 | 0.530 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2023 | 289 | 0.490 |
Why?
|
| Stem Cell Niche | 1 | 2017 | 54 | 0.490 |
Why?
|
| Transplantation, Homologous | 8 | 2024 | 668 | 0.480 |
Why?
|
| Intestines | 2 | 2017 | 587 | 0.470 |
Why?
|
| Smooth Muscle Tumor | 1 | 2014 | 2 | 0.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 1325 | 0.410 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2014 | 31 | 0.410 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2014 | 20 | 0.400 |
Why?
|
| Mediastinal Neoplasms | 1 | 2014 | 36 | 0.400 |
Why?
|
| Animals | 20 | 2025 | 33656 | 0.400 |
Why?
|
| Opportunistic Infections | 1 | 2014 | 70 | 0.400 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2015 | 163 | 0.400 |
Why?
|
| Mice | 17 | 2025 | 18157 | 0.390 |
Why?
|
| Vincristine | 1 | 2014 | 188 | 0.390 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 90 | 0.370 |
Why?
|
| Vaginal Neoplasms | 1 | 2012 | 17 | 0.360 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 310 | 0.350 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2010 | 2 | 0.330 |
Why?
|
| Histiocytic Sarcoma | 1 | 2010 | 5 | 0.330 |
Why?
|
| Immunosuppressive Agents | 2 | 2019 | 656 | 0.330 |
Why?
|
| Colitis | 2 | 2023 | 165 | 0.320 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2010 | 59 | 0.320 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2010 | 94 | 0.320 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 469 | 0.310 |
Why?
|
| Anti-Bacterial Agents | 4 | 2025 | 2574 | 0.310 |
Why?
|
| Neoplasms | 2 | 2022 | 2977 | 0.300 |
Why?
|
| Brain Neoplasms | 2 | 2025 | 1305 | 0.300 |
Why?
|
| HSP47 Heat-Shock Proteins | 2 | 2019 | 3 | 0.290 |
Why?
|
| Translocation, Genetic | 1 | 2010 | 344 | 0.280 |
Why?
|
| Humans | 32 | 2026 | 130069 | 0.280 |
Why?
|
| Gene Rearrangement | 1 | 2010 | 322 | 0.280 |
Why?
|
| Microbiota | 2 | 2025 | 435 | 0.270 |
Why?
|
| Transplantation Conditioning | 3 | 2018 | 327 | 0.270 |
Why?
|
| Middle Aged | 17 | 2026 | 28314 | 0.250 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2026 | 608 | 0.240 |
Why?
|
| Intestinal Mucosa | 3 | 2020 | 763 | 0.240 |
Why?
|
| T-Lymphocytes | 4 | 2024 | 1707 | 0.240 |
Why?
|
| Mucus | 2 | 2022 | 37 | 0.240 |
Why?
|
| Mice, Inbred BALB C | 3 | 2024 | 979 | 0.230 |
Why?
|
| Mucins | 2 | 2022 | 71 | 0.230 |
Why?
|
| Female | 23 | 2026 | 70239 | 0.220 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 4691 | 0.220 |
Why?
|
| Bacteroides thetaiotaomicron | 1 | 2024 | 8 | 0.220 |
Why?
|
| Hematologic Neoplasms | 2 | 2018 | 314 | 0.220 |
Why?
|
| Bile Ducts | 1 | 2024 | 52 | 0.210 |
Why?
|
| Immunological Synapses | 1 | 2024 | 32 | 0.200 |
Why?
|
| Fever | 1 | 2026 | 311 | 0.200 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 1366 | 0.190 |
Why?
|
| Xylose | 1 | 2022 | 6 | 0.190 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2023 | 108 | 0.190 |
Why?
|
| Carbapenems | 1 | 2022 | 45 | 0.180 |
Why?
|
| Biopsy | 2 | 2023 | 1240 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 1 | 2024 | 449 | 0.170 |
Why?
|
| Polysaccharides | 1 | 2022 | 143 | 0.170 |
Why?
|
| Stomach | 1 | 2024 | 270 | 0.170 |
Why?
|
| Fatal Outcome | 2 | 2014 | 356 | 0.170 |
Why?
|
| Bone Marrow Transplantation | 2 | 2015 | 589 | 0.170 |
Why?
|
| Lymphoma, B-Cell | 1 | 2023 | 145 | 0.170 |
Why?
|
| Adult | 12 | 2026 | 31011 | 0.170 |
Why?
|
| Organoids | 1 | 2024 | 297 | 0.170 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2020 | 228 | 0.170 |
Why?
|
| Vitamin A | 2 | 2019 | 58 | 0.170 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2021 | 2 | 0.170 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2021 | 2 | 0.170 |
Why?
|
| Glioma | 1 | 2025 | 495 | 0.160 |
Why?
|
| Filgrastim | 1 | 2020 | 13 | 0.160 |
Why?
|
| Aged | 12 | 2026 | 20821 | 0.160 |
Why?
|
| Methylamines | 1 | 2020 | 20 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 27 | 0.160 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2024 | 499 | 0.160 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2025 | 950 | 0.160 |
Why?
|
| Cyclophosphamide | 3 | 2022 | 425 | 0.160 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2020 | 35 | 0.160 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 1212 | 0.160 |
Why?
|
| Duodenal Diseases | 1 | 2020 | 28 | 0.150 |
Why?
|
| Ileal Diseases | 1 | 2020 | 26 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 126 | 0.150 |
Why?
|
| Leukemia | 1 | 2023 | 375 | 0.150 |
Why?
|
| Ileum | 1 | 2020 | 109 | 0.150 |
Why?
|
| Male | 16 | 2026 | 64379 | 0.150 |
Why?
|
| Interleukin-17 | 2 | 2022 | 125 | 0.150 |
Why?
|
| Stem Cell Transplantation | 2 | 2018 | 224 | 0.150 |
Why?
|
| Duodenum | 1 | 2020 | 111 | 0.150 |
Why?
|
| RNA, Small Interfering | 2 | 2019 | 662 | 0.150 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 232 | 0.150 |
Why?
|
| Macrophages | 2 | 2020 | 657 | 0.140 |
Why?
|
| Japan | 2 | 2018 | 160 | 0.140 |
Why?
|
| Endothelium, Lymphatic | 1 | 2018 | 10 | 0.140 |
Why?
|
| WT1 Proteins | 1 | 2018 | 23 | 0.140 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2018 | 15 | 0.140 |
Why?
|
| Incidence | 1 | 2026 | 3321 | 0.140 |
Why?
|
| Skin Physiological Phenomena | 1 | 2018 | 15 | 0.140 |
Why?
|
| Cecum | 1 | 2018 | 26 | 0.140 |
Why?
|
| Disease Models, Animal | 3 | 2024 | 4639 | 0.130 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 1580 | 0.130 |
Why?
|
| alpha-Defensins | 1 | 2017 | 6 | 0.130 |
Why?
|
| Intestinal Diseases | 1 | 2018 | 67 | 0.130 |
Why?
|
| Cytoprotection | 1 | 2017 | 37 | 0.130 |
Why?
|
| Histocompatibility Testing | 2 | 2017 | 109 | 0.130 |
Why?
|
| Metabolomics | 1 | 2021 | 499 | 0.130 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2017 | 57 | 0.130 |
Why?
|
| Lymphoma | 1 | 2020 | 327 | 0.130 |
Why?
|
| Skin Diseases | 1 | 2018 | 142 | 0.120 |
Why?
|
| Models, Biological | 1 | 2021 | 1375 | 0.120 |
Why?
|
| HLA Antigens | 1 | 2017 | 225 | 0.120 |
Why?
|
| Remission Induction | 2 | 2018 | 306 | 0.120 |
Why?
|
| Young Adult | 5 | 2018 | 9978 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 1 | 2018 | 221 | 0.120 |
Why?
|
| Colonoscopy | 1 | 2018 | 241 | 0.110 |
Why?
|
| Colitis, Ulcerative | 1 | 2018 | 208 | 0.110 |
Why?
|
| Administration, Oral | 1 | 2017 | 706 | 0.110 |
Why?
|
| Cancer Care Facilities | 1 | 2015 | 31 | 0.110 |
Why?
|
| Mannans | 1 | 2015 | 15 | 0.110 |
Why?
|
| Dry Eye Syndromes | 1 | 2019 | 295 | 0.110 |
Why?
|
| Pyrazoles | 1 | 2018 | 355 | 0.110 |
Why?
|
| Endothelial Cells | 1 | 2018 | 520 | 0.110 |
Why?
|
| Lymphoma, T-Cell | 1 | 2015 | 60 | 0.110 |
Why?
|
| Spinal Neoplasms | 1 | 2015 | 76 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2015 | 119 | 0.110 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 1317 | 0.100 |
Why?
|
| Th17 Cells | 1 | 2015 | 97 | 0.100 |
Why?
|
| Allografts | 3 | 2020 | 220 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2018 | 942 | 0.100 |
Why?
|
| HLA-DR Antigens | 1 | 2013 | 66 | 0.100 |
Why?
|
| Homeostasis | 1 | 2018 | 712 | 0.100 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 55 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 5166 | 0.100 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 204 | 0.100 |
Why?
|
| Prednisone | 1 | 2014 | 237 | 0.100 |
Why?
|
| Isoantibodies | 1 | 2013 | 62 | 0.100 |
Why?
|
| In Situ Hybridization | 1 | 2014 | 437 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 613 | 0.100 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2025 | 376 | 0.100 |
Why?
|
| Prognosis | 3 | 2018 | 4848 | 0.090 |
Why?
|
| Doxorubicin | 1 | 2014 | 289 | 0.090 |
Why?
|
| RNA, Viral | 1 | 2014 | 499 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2015 | 1481 | 0.090 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 1278 | 0.080 |
Why?
|
| Lung Diseases | 1 | 2015 | 397 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2020 | 17537 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1592 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2017 | 1906 | 0.080 |
Why?
|
| Tacrolimus | 2 | 2022 | 100 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 630 | 0.080 |
Why?
|
| Tissue Donors | 1 | 2013 | 506 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 2825 | 0.070 |
Why?
|
| Cyclosporine | 2 | 2019 | 132 | 0.070 |
Why?
|
| Mutation | 2 | 2021 | 6067 | 0.070 |
Why?
|
| Survival Rate | 3 | 2018 | 2107 | 0.070 |
Why?
|
| Liposomes | 2 | 2019 | 197 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2012 | 479 | 0.060 |
Why?
|
| Fibrosis | 2 | 2019 | 420 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2023 | 1241 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2057 | 0.060 |
Why?
|
| Dioxoles | 1 | 2024 | 13 | 0.050 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2024 | 21 | 0.050 |
Why?
|
| NFATC Transcription Factors | 1 | 2024 | 39 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2025 | 742 | 0.050 |
Why?
|
| Benzamides | 1 | 2024 | 125 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2024 | 123 | 0.050 |
Why?
|
| Human papillomavirus 16 | 1 | 2024 | 97 | 0.050 |
Why?
|
| Gene Library | 1 | 2024 | 212 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2022 | 18 | 0.050 |
Why?
|
| Propionates | 1 | 2022 | 31 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2025 | 6401 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3739 | 0.050 |
Why?
|
| Machine Learning | 1 | 2026 | 379 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2022 | 54 | 0.040 |
Why?
|
| Time Factors | 1 | 2012 | 6165 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2023 | 189 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 352 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2023 | 492 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2022 | 3810 | 0.040 |
Why?
|
| Colony-Stimulating Factors | 1 | 2021 | 3 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2025 | 706 | 0.040 |
Why?
|
| Adolescent | 4 | 2020 | 20794 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 639 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2024 | 905 | 0.040 |
Why?
|
| Goblet Cells | 1 | 2020 | 105 | 0.040 |
Why?
|
| Atrophy | 1 | 2020 | 246 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1475 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2019 | 130 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 889 | 0.040 |
Why?
|
| Autocrine Communication | 1 | 2018 | 29 | 0.040 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2019 | 93 | 0.030 |
Why?
|
| Hair Follicle | 1 | 2018 | 30 | 0.030 |
Why?
|
| Drug Dosage Calculations | 1 | 2017 | 21 | 0.030 |
Why?
|
| Histocompatibility | 1 | 2017 | 42 | 0.030 |
Why?
|
| Antilymphocyte Serum | 1 | 2017 | 44 | 0.030 |
Why?
|
| Myofibroblasts | 1 | 2018 | 62 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2023 | 758 | 0.030 |
Why?
|
| Lacrimal Apparatus | 1 | 2019 | 124 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2017 | 124 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 820 | 0.030 |
Why?
|
| Nitriles | 1 | 2018 | 161 | 0.030 |
Why?
|
| Epithelium | 1 | 2018 | 334 | 0.030 |
Why?
|
| Liver | 1 | 2024 | 1783 | 0.030 |
Why?
|
| Collagen | 1 | 2018 | 274 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 258 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 3713 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2012 | 12818 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 902 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1102 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2018 | 290 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 331 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1265 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2019 | 850 | 0.030 |
Why?
|
| Candida albicans | 1 | 2015 | 87 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2018 | 454 | 0.030 |
Why?
|
| Candidiasis | 1 | 2015 | 132 | 0.030 |
Why?
|
| Risk Factors | 2 | 2018 | 10959 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 1014 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 630 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 525 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2015 | 542 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2015 | 765 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 2289 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 1205 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1800 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 2885 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 2548 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6765 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 4645 | 0.020 |
Why?
|